Picture loading failed.

Anti-CCR5 therapeutic antibody (Pre-made Leronlimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19,[1][2] triple negative breast cancer, and HIV infection.[4] The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015. In February 2018, Cytodyn Inc reported that the primary endpoint had been achieved in the PRO 140 pivotal combination therapy trial in HIV infection. In 2020 CytoDyn submitted a fast-track biologics license application for treatment of CCR5-tropic HIV-1 Infection.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-304-1mg 1mg 3090
GMP-Bios-ab-304-10mg 10mg 21890
GMP-Bios-ab-304-100mg 100mg 148000
GMP-Bios-ab-304-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CCR5 therapeutic antibody (Pre-made Leronlimab biosimilar,Whole mAb)
INN Name Leronlimab
TargetCCR5
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesCytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute
Conditions Approvedna
Conditions ActiveHIV infections;HIV-1 infections;Graft-versus-host disease;Breast cancer;Colorectal cancer;Non-alcoholic steatohepatitis;Prostate cancer;COVID-19;Autoimmune disorders;Stroke;Traumatic brain injuries
Conditions Discontinuedna
Development Techna